Denali therapeutics announces broad pipeline progress including positive results from its lrrk2 program for parkinson's disease

Denali therapeutics announces broad pipeline progress including positive results from its lrrk2 program for parkinson's disease.denali therapeutics inc - ind submitted for dnl310 for hunter syndrome.denali therapeutics inc - cta approved for dnl343.denali therapeutics inc - ripk1 inhibitor dnl747 phase 1b trials in alzheimer's and als fully enrolled.denali therapeutics -intends to select dnl201 or dnl151 in mid-2020 to advance into phase 2/3 clinical trials in patients with parkinson's disease.
DNLI Ratings Summary
DNLI Quant Ranking